Payment overview · 2025
General Payments
$407.26
22 reported records · 7 companies
Healthcare provider profile · identity verified
Mikhail Bernshteyn, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1427056878
Verified facts
What the public records show
CMS Open Payments records show Mikhail Bernshteyn, MD received $407.26 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 51.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Nurtec Odt, Ozempic, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 358 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Zenpep by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EUCRISA as an associated drug or biological on 1712 records involving 991 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Eucrisa by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $210.59 | 51.7% | 14 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.69 | 15.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.20 | 11.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.99 | 6.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.22 | 5.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.94 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.63 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $407.26 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $210.59 | 14 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $184.90 | 13 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $63.69 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.20 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 312 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 358 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 182 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
312 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
358 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
182 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | EUCRISA open payments reported associated product |
CMS Open Payments — General Payments 1712 supporting records · 991 recipient NPIs · example record 1228794851 |
Eucrisa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 441 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 77 |
| Diclofenac Sodium | Diclofenac Sodium | 429 | 77 |
| Linzess | Linaclotide | 358 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 351 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 331 | 51 |
| Creon | Lipase/Protease/Amylase | 312 | 47 |
| Losartan Potassium | Losartan Potassium | 310 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 57 |
| Dexlansoprazole Dr | Dexlansoprazole | 293 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 43 |
| Simvastatin | Simvastatin | 238 | 37 |
| Clonidine Hcl | Clonidine Hcl | 229 | 37 |
| Omeprazole | Omeprazole | 224 | 44 |
| Furosemide | Furosemide | 216 | 39 |
| Vascepa | Icosapent Ethyl | 211 | 31 |
| Metformin Hcl | Metformin Hcl | 191 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 188 | 29 |
| Zenpep | Lipase/Protease/Amylase | 182 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 32 |
| Celecoxib | Celecoxib | 176 | 23 |
| Gabapentin | Gabapentin | 172 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 58 |
| Ibuprofen | Ibuprofen | 162 | 48 |
| Meclizine Hcl | Meclizine Hcl | 159 | 34 |
| Ozempic | Semaglutide | 156 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 29 |
| Eliquis | Apixaban | 151 | 24 |
| Azithromycin | Azithromycin | 149 | 108 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 25 |
| Myrbetriq | Mirabegron | 135 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 30 |
| Allopurinol | Allopurinol | 117 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 115 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 19 |
| Lidocaine | Lidocaine | 108 | 23 |
| Lisinopril | Lisinopril | 107 | 17 |
| Meloxicam | Meloxicam | 102 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 95 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 94 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 94 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 15 |
| Benazepril Hcl | Benazepril Hcl | 93 | 14 |
| Nifedipine Er | Nifedipine | 92 | 16 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 89 | suppressed |
| Atenolol | Atenolol | 85 | 12 |
| Mounjaro | Tirzepatide | 83 | 14 |
| Ketoconazole | Ketoconazole | 81 | 12 |
| Entresto | Sacubitril/Valsartan | 80 | suppressed |
| Restasis | Cyclosporine | 79 | suppressed |
| Potassium Chloride | Potassium Chloride | 78 | 16 |
| Glipizide | Glipizide | 77 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 77 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 11 |
| Nitroglycerin | Nitroglycerin | 75 | 16 |
| Famotidine | Famotidine | 74 | 18 |
| Synthroid | Levothyroxine Sodium | 73 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 72 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | suppressed |
| Glimepiride | Glimepiride | 71 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 19 |
| Alprazolam | Alprazolam | 68 | 16 |
| Ezetimibe | Ezetimibe | 68 | 15 |
| Trazodone Hcl | Trazodone Hcl | 68 | 12 |
| Memantine Hcl | Memantine Hcl | 64 | suppressed |
| Valsartan | Valsartan | 64 | 16 |
| Hydrocortisone | Hydrocortisone | 62 | 14 |
| Montelukast Sodium | Montelukast Sodium | 62 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 61 | suppressed |
| Carvedilol | Carvedilol | 60 | 13 |
| Finasteride | Finasteride | 59 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 59 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | suppressed |
| Mupirocin | Mupirocin | 58 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 15 |
| Ammonium Lactate | Ammonium Lactate | 56 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 49 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 46 | 40 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 13 |
| Valacyclovir | Valacyclovir Hcl | 45 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 11 |
| Lactulose | Lactulose | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Tradjenta | Linagliptin | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Digoxin | Digoxin | 39 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 27 |
| Clobetasol Propionate | Clobetasol Propionate | 38 | suppressed |
| Colchicine | Colchicine | 38 | suppressed |
| Felodipine Er | Felodipine | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 31 |
| Dexilant | Dexlansoprazole | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 35 | suppressed |
| Loperamide | Loperamide Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 12 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 32 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Dexamethasone | Dexamethasone | 31 | 25 |
| Lorazepam | Lorazepam | 31 | 12 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | 13 |
| Ssd | Silver Sulfadiazine | 29 | suppressed |
| Bystolic | Nebivolol Hcl | 28 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 27 | suppressed |
| Multaq | Dronedarone Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 14 |
| Eplerenone | Eplerenone | 22 | suppressed |
| Eucrisa | Crisaborole | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Micardis | Telmisartan | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | suppressed |
| Proctozone-Hc | Hydrocortisone | 21 | suppressed |
| Tavaborole | Tavaborole | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 18 |
| Ibu | Ibuprofen | 20 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Naproxen Sodium Er | Naproxen Sodium | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Travoprost | Travoprost | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Ivermectin | Ivermectin | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Welchol | Colesevelam Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amcinonide | Amcinonide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Alogliptin-Pioglitazone | Alogliptin Benz/Pioglitazone | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Fioricet With Codeine | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Horizant | Gabapentin Enacarbil | 12 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Gralise | Gabapentin | 11 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Prozac | Fluoxetine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $407.26 · 22 records | ABBVIE INC. | CREON, GEMTESA, LINZESS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, Symbravo, ZAVZPRET, ZENPEP | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error